This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Watson, J. C. Articles by Ulatowski, J. A. Search for Related Content PubMed PubMed Citation Articles by Watson, J. C. Articles by Ulatowski, J. A.

(Stroke. 1997;28:1624-1630.)
© 1997 American Heart Association, Inc.

Articles

Effects of the Allosteric Modification of Hemoglobin on Brain Oxygen and Infarct Size in a Feline Model of Stroke

Joe C. Watson, MD; Egon M. R. Doppenberg, MD; M. Ross Bullock, MD, PhD; Alois Zauner, MD; Melody R. Rice, BS; Donald Abraham, PhD Harold F. Young, MD

From the Division of Neurosurgery and Department of Medicinal Chemistry (D.A.), Medical College of Virginia, West Hospital, Virginia Commonwealth University, Richmond.

Correspondence to M. Ross Bullock, MD, PhD, Division of Neurological Surgery, Medical College of Virginia, Virginia Commonwealth University, West Hospital, 8th Floor, Box 631, Richmond, VA 23298-0631. E-mail RBULLOCK{at}Gems.VCU.Edu

Background and Purpose Cerebral ischemia and stroke are leading causes of morbidity and mortality. An approach to protecting the brain during ischemia is to try to increase the delivery of oxygen via the residual blood flow through and around ischemic tissue. To test this hypothesis, we used a novel oxygen delivery agent, RSR-13 (2-[4-[[(3,5-dimethylanilino)-carbonyl]-methyl]phenoxy]-2-methylpropionic acid). Intravenous administration of RSR-13 increases oxygen delivery through allosteric modification of the hemoglobin molecule, resulting in a shift in the hemoglobin/oxygen dissociation curve in favor of oxygen delivery.

Methods We studied RSR-13 in a feline model of permanent middle cerebral artery occlusion to assess its effects on cerebral oxygenation and infarct size. A randomized, blinded study of RSR-13 (n=6) versus 0.45% saline (n=12) was conducted, after an RSR-13 dose-escalation study (n=4). Drug was administered as a preocclusion bolus followed by a continuous infusion for the duration of the experiment (5 hours). Brain oxygen was measured continuously with the use of a Clark oxygen electrode. Infarct size was measured at 5 hours after occlusion with computer-assisted volumetric analysis.

Results The drug treatment group had consistently higher mean brain oxygen tension than controls (33±5 and 27±6 mm Hg, respectively) and significantly smaller infarcts (21±9% versus 33±9%, respectively; P<.008). We observed an inverse relationship between the dose response of RSR-13 (the shift in the hemoglobin/oxygen dissociation curve) and infarct size.

Conclusions These results are evidence that allosteric hemoglobin modification is protective to the brain after acute focal ischemia, providing a new opportunity for neuroprotection and raising the possibility of enhancing the protective effect of thrombolysis and ion channel blockade.

Editorial Comment

John A. Ulatowski, MD, PhD, Guest Editor

Department of Anesthesiology, Johns Hopkins Hospital, Baltimore, Md

This article has been cited by other articles:

				J. H. Suh, B. Stea, A. Nabid, J. J. Kresl, A. Fortin, J.-P. Mercier, N. Senzer, E. L. Chang, A. P. Boyd, P. J. Cagnoni, et al. Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases J. Clin. Oncol., January 1, 2006; 24(1): 106 - 114. [Abstract] [Full Text] [PDF]

				O. Eichelbronner, M. D'Almeida, A. Sielenkamper, W. J. Sibbald, and I. H. Chin-Yee Increasing P50 does not improve DO2CRIT or systemic VO2 in severe anemia Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H92 - H101. [Abstract] [Full Text] [PDF]

				M. S. Wainwright, H. Sheng, Y. Sato, G. Burkhard Mackensen, R. P. Steffen, R. D. Pearlstein, and D. S. Warner Pharmacological correction of hypothermic P50 shift does not alter outcome from focal cerebral ischemia in rats Am J Physiol Heart Circ Physiol, May 1, 2002; 282(5): H1863 - H1870. [Abstract] [Full Text] [PDF]

				J. A. Wahr, M. Gerber, J. Venitz, and N. Baliga Allosteric Modification of Oxygen Delivery by Hemoglobin Anesth. Analg., March 1, 2001; 92(3): 615 - 620. [Abstract] [Full Text] [PDF]

				K. S. Kilgore, C. F. Shwartz, M. A. Gallagher, R. P. Steffen, R. S. Mosca, and S. F. Bolling RSR13, a Synthetic Allosteric Modifier of Hemoglobin, Improves Myocardial Recovery Following Hypothermic Cardiopulmonary Bypass Circulation, November 9, 1999; 100(90002): II-351 - 356. [Abstract] [Full Text] [PDF]

				H. P. Grocott, R. D. Bart, H. Sheng, Y. Miura, R. Steffen, R. D. Pearlstein, D. S. Warner, and E. P. Wei Effects of a Synthetic Allosteric Modifier of Hemoglobin Oxygen Affinity on Outcome From Global Cerebral Ischemia in the Rat • Editorial Comment Stroke, August 1, 1998; 29(8): 1650 - 1655. [Abstract] [Full Text] [PDF]